FARMINGDALE, NY — March 2026 — Enzo Life Sciences, Inc. (NYSE: ENZ), a pioneer in life sciences research and diagnostic solutions, today announced the completion of a major expansion to its cGMP manufacturing facility in Farmingdale, New York.

The expansion adds approximately 15,000 square feet of state-of-the-art manufacturing space, increasing the company's capacity for production of diagnostic reagents, therapeutic-grade biochemicals, and custom formulations under current Good Manufacturing Practice (cGMP) conditions.

Key Highlights

• New cleanroom suites meeting ISO Class 7 standards
• Expanded cold-chain storage with -80°C ultra-low freezer capacity
• Advanced quality control laboratory with HPLC, mass spectrometry, and spectrophotometry capabilities
• Dedicated packaging and labeling lines for clinical and IVD products
• Increased capacity for custom and OEM manufacturing partnerships

Supporting Growing Demand

"This expansion reflects the growing demand for high-quality, domestically manufactured reagents across the pharmaceutical, diagnostic, and research markets," said the CEO of Enzo Life Sciences. "Our investment in expanded cGMP capabilities positions us to better serve our customers with faster turnaround, greater flexibility, and the quality standards they rely on."

The expanded facility will support production across multiple product lines including ELISA kits, antibody conjugates, nucleic acid labeling reagents, and custom biochemicals. The company expects the new capacity to become fully operational in Q2 2026.

About Enzo Life Sciences

Enzo Life Sciences, a subsidiary of Enzo Biochem, Inc. (NYSE: ENZ), manufactures and distributes a broad portfolio of over 11,000 products to research and clinical laboratories worldwide. With over 40 years of experience, Enzo provides innovative solutions in genomics, proteomics, cell biology, and clinical diagnostics. For more information, visit www.enzo.com.